Evaluation of Iodine Supplementation in Women With Pregnancy Associated With Gestational Diabetes. IODIAB Study

DURED DARDARI (✉ dured.dardari@gmail.com)
Centre Hospitalier Sud Francilien https://orcid.org/0000-0002-7172-4300

François-Xavier Labome
Centre Hospitalier Sud Francilien

Caroline Tourte
Centre Hospitalier Sud Francilien

Elodie Henry
Centre Hospitalier Sud Francilien

Alfred Penfornis
Centre Hospitalier Sud Francilien

Research Article

Keywords: iodine, gestational diabetes, WHO, Health

Posted Date: November 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-921852/v1

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Iodine supplementation is indicated by the French High Authority for Health (HAS) and by the World Health Organization (WHO) during pregnancy. We want to know if this supplementation is prescribed in a manner consistent with the HAS and WHO recommendations in women diagnosed with gestational diabetes mellitus.

Results:

Recruitment for the study will start August 2021 and will be ended in October 2021, with the final study results scheduled for December 2021.

Conclusion

The objective of the Iododiab study is to assess whether practitioners caring for women with gestational diabetes mellitus prescribe iodine supplementation according to the recommendations of the French High Authority for Health and by the World Health Organization.

Introduction

In pregnancy we observe (i) increasing in serum thyroxine-binding globulin (TBG) concentrations, (ii) an elevation in renal blood flow and glomerular filtration which lead to an increased iodide clearance from plasma and, hence, to an obligatory loss of iodine. (iii) Increased activity of type 3 deiodinase in the placenta increases the degradation of thyroxine (T₄) to the inactive form reverse triodothyronine (T₃) [1]. Thyroid hormone is essential for neurodevelopment both in utero and early in life [2], severe iodine deficiency causes a range of disorders which include hypothyroidism, goiter and profound impairment of growth and neurodevelopmental [3], it is well established that correcting severe iodine deficiency leads to better clinical outcomes, including reduced cretinism and infant mortality rates [4], of late there are concerns increasingly that even mild to moderate iodine deficiency leads to adverse clinical outcomes, including potentially reduced intelligence quotient (IQ) in offspring [5,6].

The physiological requirements for iodine are increased in pregnant women, going from 150 μg / day to 250 μg / day. The iodine intake is assessed by the iodine concentration in the urine, the target of which in pregnant women is ioduria between 150 and 250 μg / l [7]. In French the general population is not deficient in iodine according to the national nutrition health study in 2006–2007, with a median ioduria of 136 μg / l (therefore greater than 100 μg / l) for all elderly adults 18–74 years old [8], [9]. However, according to the French studies by Raverot et al., Luton et al. And Hieronimus et al, the median ioduria of pregnant women is between 50 and 100 μg / l, which suggests a moderate iodine deficiency [10], [11], [12]. To maintain euthyroidism, the mother must increase its production of T4 by 40–50% (10–150%), which requires an additional iodine intake of 150-250 μg / d [13], [14], [15]. The thyroid contains a reserve of iodine, but this is depleted during pregnancy without supplementation.
The world health organization (WHO), United Nations of International Children's Emergency Fund (UNICEF) international council for control of iodine deficiency disorders (ICCIDD) recommend a systematic iodine intake during pregnancy of at least 250 µg / day. this supplementation should be facilitated by adding 150 µg / d of iodine to all polyvitamin and mineral preparations intended for pregnant women [16].

In another register, according to the WHO definition, gestational diabetes (GDM) is a disorder of carbohydrate tolerance leading to hyperglycemia of varying severity, beginning or diagnosed for the first time during pregnancy, from the diagnosis of GDM. it is assumed that the pregnant woman benefits from personalized care.

**Description And Rationale Of The Study Method**

The study protocol was approved by the French National Agency for Medicines and Health Products Safety (ANSM) and by the ethics committee of Agneres University Hospital (Institutional Review Board; Agreement of Department of Health and Human Services No. RCB : 2020-A02570-39) Comprehensive information on the study was provided to each patient on a form printed specifically for this purpose, the study received a registration on the clinical trial.gouve system with the number: NCT04683211

**STUDY OBJECTIVES**

**Main and secondary objectives:**

We wish to examine whether in women having a pregnancy benefiting from a personalized follow-up linked to a diagnosis of gestational diabetes, iodine supplementation is implemented according to WHO recommendations, ie 250 µg / day. Primary Evaluation Criterion: Iodic supplementation prescribed in µg / d

Secondary objectives: evaluation of iodic supplementation according to prescriber (midwife versus general practician or gynecologist). Secondary evaluation criterion odic supplementation prescribed in µg / day by midwive, iodic supplementation prescribed in µg / prescribed by the general practitioner and iodic supplementation prescribed in µg / day by gynecologists.

**Participants**

Inclusion criteria: Pregnant woman with gestational diabetes confirmed by un abnormal fasting glucose or by oral hyperglycemia test, age ≥ 18 years, subject informed of the study and not having opposed it. Non-inclusion criteria: Already known thyroid pathology.

**Key Data Collected and the outcome of the study**

Upon arrival at the reception consultation for the management of gestational diabetes, the information note will be given to the patient. During the consultation, the investigator will explain the study and obtain
the patient’s agreement to participate. The questionnaire will then be given to the patient.

There are no plans to follow up patients in this study. Participation consists of completing the questionnaire.

**Data collected:** The participants will answer to a questionary included the following questions: The term of pregnancy (in weeks), the parity (number of pregnancies), if the participants have a chronic pathology? If so, which one? which treatment? if the patient in known to have a pathology of the thyroid gland? If so, which therapy. Have the participant received a prescription for iodine supplementation since the start of pregnancy, If so, which one, for how long, at what dose. If there is iodic supplementation, who prescribed the prescription (midwife, attending physician, gynecologist. Are the lady receiving folic acid? During your previous pregnancies, did you receive vitamin supplementation? If yes which one?

**STATISTICAL methods**

Statistical justification for the sample size

We hypothesize that one in 2 patients receives iodine supplementation at 250μg / d. The number of patients is therefore 97 patients.

**Description of statistical methods**

The descriptive analysis will include for each quantitative parameter: mean, standard deviation, median, interquartiles, minimum, maximum. The qualitative parameters will be expressed by their number and corresponding percentage.

If \( p \) is the expected percentage, its confidence interval, considered at 20%, is: \( p \pm 1.96 \times \sqrt{\frac{p \times (1-p)}{n}} \)

If \( d \) is the distance between the estimate of the percentage and the bounds of its confidence interval, we must solve the equation:

\[
d = 1.96 \times \sqrt{\frac{p \times (1-p)}{n}}
\]

\[=> n = 1.96^2 \times 2 \times p \times (1-p) / d^2 = 97 \text{ patients}\]

The analysis will be performed using R software (R version 3.5.0 (2018-04-23) © 2018 The R Foundation for Statistical Computing).

**Discussion**

Iodic supplementation during pregnancy is indicated according to the recommendations of the World Health Organization and by the high Health French authority, the main objective of the iodiab study is to assess whether the prescription of this supplement is respected by the wise woman, the general
practitioner and by the gynecologist who are supposed to offer a personalized follow-up for women with a diagnosis of pregnancy diabetes.

Recruitment for the iodiab study will start in August, the inclusion period is 3 months, the results will be published in December 2021

**Declarations**

**Funding:** Not applicable

**Conflicts of interest:** All authors declare that they have non conflicts of interest with the study

**Competing interests:** Not applicable

**Availability of data and material:** all data are available in the manuscript

**Code availability:** Not applicable

**Authors’ contributions** DD and AP create the study and wrote the manuscript, FL, CT and EH contribute for collecting data, Formal analysis and investigation, alla authors approve the manuscript

**Ethics approval:** ethics committee of Agneres University Hospital (Institutional Review Board; Agreement of Department of Health and Human Services No. RCB : 2020-A02570-39)

**Consent to participate and for publications:** participated patients gave a written content to participate for the study and for the results publications

**References**

1. A.M. Leung, E.N. Pearce, L.E. Braverman Iodine nutrition in pregnancy and lactation Endocrinol Metab Clin N Am, 40 (2011), pp. 765-777
2. Rovet, J.F. (2014) The role of thyroid hormones for brain development and cognitive function. *Endocr Development*, 26, 26–43.
3. Zimmermann, M.B. (2009) Iodine deficiency. *Endocrine Reviews*, 30, 376–408.
4. Hetzel,B.S. (1983) Iodine deficiency disorders (IDD) and their eradication. *Lancet*, 2, 1126–1129.
5. Zimmermann, M.B. (2007) The adverse effects of mild-to-moderate iodine deficiency during pregnancy and childhood: a review. *Thyroid*, 17, 829–835.
6. Taylor, P.N., Okosieme, O.E., Dayan, C.M. *et al.* (2014) Therapy of endocrine disease: Impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. *European Journal of Endocrinology*, 170, R1–R15.
7. World Health Organization, Geneva 2005 Prevention and control of iodine deficiency in pregnant and lactating women and in children less than two years old: conclusions and recommendations of the
technical consultation Public Health Nutr, 10 (12A) (2007), pp. 1606-1611

8. Unité de surveillance et d'épidémiologie nutritionnelle, InVS, Université Paris 13 Déficiency en iode. L'état de santé de la population en France – suivi des objectifs annexés à la loi de santé publique – rapport [en ligne], Ministère des affaires sociales et de la santé, Direction de la recherche, des études, de l'évaluation et des statistiques, Paris (2011), pp. 144-145

9. World Health Organization, United Nations Children's Fund, International Council for the Control of Iodine Deficiency Disorders 2007 Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers (3rd ed.), World Health Organization, Geneva (2007)

10. V. Raverot, C. Bournaud, G. Sassolas, J. Orgiazzi, F. Claustrat, P. Gaucherand, et al. Pregnant French women living in the Lyon area are iodine deficient and have elevated serum thyroglobulin concentrations Thyroid, 22 (5) (2012), pp. 522-528

11. D. Luton, C. Alberti, E. Vuillard, G. Ducarme, J.F. Oury, J. Guibourdenche Iodine deficiency in Northern Paris area: impact on fetal thyroid mensuration PLoS One, 6 (2) (2011), p. e14707

12. S. Hiéronimus, M. Bec-Roche, P. Ferrari, N. Chevalier, P. Fénichel, F. Brucker-Davis Statut iodé et fonction thyroïdienne chez 330 femmes de la région niçoise évaluées en 2ème partie de grossesse Ann Endocrinol, 70 (2009), pp. 218-224

13. International Council for the Control of Iodine Deficiency Disorders Iodine requirements in pregnancy and infancy ICCIDD Newsletter, 23 (2007), pp. 1-2

14. C. Bournaud, J. Orgiazzi Thyroïde et grossesse Ann Endocrinol, 64 (4) (2003), pp. 324-331

15. F. Delange Iodine requirements during pregnancy, lactation and the neonatal period and indicators of optimal iodine nutrition Public Health Nutr, 10 (12A) (2007), pp. 1571-1580

16. EASTMAN CJ. Recommandation of a 2005 WHO Technical Consultation Group. 23th International Thyroid Congress, Buenos Aires, Argentina, 2005

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- DUREDIODIABprotorniv1.020201006CTE2en.docx
- SPIRITChecklistdownload8Jan1311.doc